The Daily Pulse

Health• Updated

Supreme Court Questions Huge Gap in Cancer Drug Prices

Reported by Kavya Rao (Senior Writer) · The Hindu - Health ·

Verified — Confirmed by a second source: Bing News - Health (India)

Confirmed by a second source: Bing News - Health (India)

Important
Supreme Court Questions Huge Gap in Cancer Drug PricesPhoto: Wikimedia Commons

UPDATE - follow-up to Who decides the cost of medicines in India?: A cancer medicine supplied to a retailer for ₹2,700 carries a maximum retail price of ₹27,000, prompting the Supreme Court to question the massive gap in September 2026.

Trade Margin Cap

Following this scrutiny, the National Pharmaceutical Pricing Authority announced a 30% cap on trade margins for 137 anti-cancer drugs, which took effect on November 9. This intervention could lower prices significantly for patients buying certain products.

Context

India's drug price controls trace back to the Defence of India Act during the 1962 Sino-Indian War. Balancing medicine licensing under the Central Drugs Standard Control Organisation and pricing under the pricing authority remains a key policy challenge.

Background: This follows an earlier report, covered earlier on 02 Nov 2026: 'Who decides the cost of medicines in India?'. Read the earlier report →

ExplainerWhy this matters

What Happened

The Supreme Court questioned the large price gap between what retailers pay for cancer medicines and what patients are charged, leading the National Pharmaceutical Pricing Authority to cap trade margins at 30% for 137 anti-cancer drugs.

Why It Matters

High medicine prices place a heavy financial burden on patients and their families, especially for critical illnesses like cancer. Capping trade margins directly limits excessive markups by the supply chain, making essential treatments more affordable.

What Happens Next

Authorities will monitor the implementation of the new caps starting November 9, while policymakers continue to evaluate how better coordination between drug licensing and pricing bodies can address broader healthcare costs.

Read more at The Hindu - Health →